Katherine Collins, Associate, Patent Attorney (Life Sciences) at IP firm Mewburn Ellis
25 April 2024NewsBiotechnologyKatherine Collins
Meeting the cell and gene therapy scale-up challenge
Improving patient access is a UN goal but for companies transitioning from trials to full-scale production, IP is essential, explains Katherine Collins of Mewburn Ellis.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 April 2024 Ex-head of Kramer Levin life sciences practice leaves for new firm | 20 years of experience includes numerous multi-billion dollar cases for some of the world’s best-selling drugs.
14 March 2024 Japanese imaging and electronics firm has acquired non-exclusive licence from ERS Genomics | Technology will be used by Elixirgen Scientific, acquired by Ricoh in 2022.